Table I.
Patient characteristics.
| Patient characteristics | Total (n=74) | HR+/HER2- (n=30) | HR+/HER2+ (n=16) | HR-/HER2+ (n=10) | HR-/HER2- (n=18) | P-value |
|---|---|---|---|---|---|---|
| Age, years, median (range) | 48 (30-78) | 44 (30-78) | 50 (37-69) | 58 (45-71) | 50 (33-78) | 0.14 |
| Stage prior to NAC, n (%) | 0.11 | |||||
| 2 | 53 (71.6) | 21 (70.0) | 15 (93.8) | 6 (60.0) | 11 (61.1) | |
| 3 | 21 (28.4) | 9 (30.0) | 1 (6.3) | 4 (40.0) | 7 (38.9) | |
| Tumor-stage prior to NAC, n (%) | 0.58 | |||||
| T1 | 13 (17.6) | 5 (16.7) | 5 (31.3) | 1 (10.0) | 2 (11.1) | |
| T2 | 48 (64.9) | 20 (66.7) | 10 (62.5) | 7 (70.0) | 11 (61.1) | |
| T3 | 11 (14.9) | 5 (16.7) | 1 (6.3) | 1 (10.0) | 4 (22.2) | |
| T4 | 2 (2.7) | 0 (0.0) | 0 (0.0) | 1 (10.0) | 1 (5.6) | |
| Node-stage prior to NAC, n (%) | 0.61 | |||||
| N0 | 12 (16.2) | 3 (10.0) | 3 (18.8) | 2 (20.0) | 4 (22.2) | |
| N1 | 51 (68.9) | 23 (76.7) | 12 (75.0) | 6 (60.0) | 10 (55.6) | |
| N2 | 2 (2.7) | 1 (3.3) | 0 (0.0) | 1 (10.0) | 0 (0.0) | |
| N3 | 9 (12.2) | 3 (10.0) | 1 (6.3) | 1 (10.0) | 4 (22.2) | |
| Type of lesion on MRI, n (%) | 0.58 | |||||
| Mass | 27 (36.5) | 9 (30.0) | 7 (43.8) | 3 (30.0) | 8 (44.4) | |
| Non-mass | 40 (54.1) | 19 (63.3) | 9 (56.3) | 5 (50.0) | 7 (38.9) | |
| NA | 7 (9.5) | 2 (6.7) | 0 (0.0) | 2 (20.0) | 3 (16.7) | |
| Histology, n (%) | 0.74 | |||||
| IDC | 71 (95.9) | 28 (93.3) | 16 (100.0) | 9 (90.0) | 18 (100.0) | |
| ILC | 1 (1.4) | 1 (3.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Metaplastic carcinoma | 2 (2.7) | 1 (3.3) | 0 (0.0) | 1 (10.0) | 0 (0.0) |
HR, hormone receptor; HER2, human epidermal growth factor receptor 2; NAC neoadjuvant chemotherapy; MRI, magnetic resonance imaging; NA, not available; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma.